Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii

• Status: Unknown status
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study assesses the effect of quadruple therapy for H. pylori, with the addition of probiotics Saccharomyces boulardii. In addition, he assesses whether this combination reduces the frequency of adverse effects of eradication therapy, and whether it affects the compliance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinical Centre of Serbia
• Treatments: Amoxicillin; Clarithromycin; Metronidazole; Rabeprazole

Criteria

Inclusion Criteria:

• Dyspepsia

• Patients not treated for H. Pylori

• Age of 18-50 years

• Positive urea breath test

Exclusion Criteria:

• Alarm symptoms (anemia, persistent vomiting, hematemesis, dysphagia, significant weight loss, palpable mass in abdomen)

• Gastric cancer

• Immunosuppressive therapy

• Use of acetylsalicylic acid

• Severe renal failure

• Severe liver failure

• Immunodeficiency

• Proven malignant disease

• Penicillin allergy

• Allergy to any component of dietary supplement (Saccharomyces boulardii and Vitamin D)

• Chronic alcoholism

• Pregnancy

• Lactation